Late-onset Pompe disease is a metabolic myopathy caused by a defi ciency of acid alpha glucosidase and is primarily characterised by progressive muscle weakness and loss of respiratory function. Alglucosidase alfa enzyme replacement therapy (ERT) is a licensed treatment for this condition.
P = 0.3879; 56.8 ± 22.6, median 53 at baseline, and 58.3 ± 22.5, median 55 at 4 years, P = 0.2187, respectively). At 2 years, the estimated mean changes in SNIP from follow-up at baseline favoured alglucosidase alpha (37.36 ± 20, median 32 at baseline and 48.7 ± 19, median 49 at 2 years, P = 0.0105), whereas at 4 years from baseline, the estimated mean SNIP did not show any signifi cant change (34.25 ± 22, median 27 at baseline and 40.75 ± 16, median 41.5 at 4 years, P = 0.1787). The 6-minute walk test between the 2 and 4 years (P = 0.422) of ERT remained similar. There were signifi cant changes from baseline in the CK levels (627 ± 327, median 526 at baseline; 426 ± 188, median 436 at 2 years; P = 0.001 and 350 ± 174, median 310 at 4 years; P = 0.0011). At 2 and 4 years, the estimated mean changes in SF-36 mental questionnaire from follow-up at baseline showed no signifi cant change (P = 0.16 and P = 0.26, respectively). Similarly, SF-36 physical questionnaire results were not remarkably different at 2 and 4 years from the follow-up at baseline (P = 0.24 and P = 0.47, respectively). The reliance on artifi cial ventilation was 6/24 prior to vs 14/24 patients during ERT. In all, 3/24 vs 4/24 patients were wheelchair bound prior to and during the ERT, respectively.
CONCLUSIONS
In this study, cohort treatment with alglucosidase alpha suggests stabilization of pulmonary function over a 4-year period; however, reliance on ventilation and mobility aids increased. *Correspondence to: Karolina M. Stepien, The Mark Holland Metabolic Unit, Salford Royal Hospital NHS Foundation Trust, Salford, UK. E-mail: kstepien@doctors.org.uk.
